Day: May 31, 2021

Nasdaq CopenhagenLondon Stock ExchangeOther stakeholders Date        31.05.2021 Share buy-back programme – week 21 The share buy-back programme runs from and including 4 February 2021 up to and including 30 July 2021. During this period Ringkjøbing Landbobank will buy-back shares to a maximum market value of DKK 255 million under a share buy-back programme, see company announcement of 3 February 2021. The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been made under the programme:Date Number of shares Average purchase price (DKK) Total purchased under the programme (DKK)Total in accordance with the last announcement240,800606.92146,145,71324...

Invalda INVL’s equity at the end of March this year was EUR 86 million, or EUR 7.36 per share, which is 3.5% larger than at the end of 2020. In the first quarter of this year Invalda INVL had a profit of EUR 2.8 million. In the same period last year it had a loss of EUR 10.6 million.  The group’s client assets under management at the end of the first quarter totalled EUR 1.33 billion, which is 6.4% more than at the start of 2021 (EUR 1.25 billion). Asset management business “The start of the year was successful for most of the funds that the group manages, with gains of EUR 62.9 million earned for clients in the first quarter. That, to a significant degree, is also why assets under management grew. Nonetheless, reduced management fees for 2nd pillar pension funds and a lack of success fee income negatively affected the quarterly results...

    Condemnation of the companies Neo Medical SAS and Neo Medical SA for counterfeit     Neo Medical prohibited from importing and marketing its Pedicle Screw Kits in France     Destruction of the Inventories of Neo Medical SAS of Pedicle Screw Kit under control of bailiff.Éragny-sur-Oise, France, May 31st, 2021 at 8:35 a.m. CET – Safe Orthopaedics (FR0013467123 – ALSAF), a company specialised in the design, manufacture and marketing of ready-to-use technologies for back surgery, with a particular focus on the treatment of emergency vertebral fractures, announced the judgment of May 28, 2021 rendered by the 3rd Chamber of the Judicial Court of Paris in the infringement case against Neo Medical.  Having discovered that the French and Swiss companies Neo Medical were importing and offering for sale on French territory products which,...

Zurich | London, 31 May 2021 – 21Shares, the pioneering Swiss Crypto ETP issuer, has chosen CryptoCompare, the digital asset market data specialist, to provide settlement pricing for all of its single asset ETP data effective June 1st 2021. The daily delivery of high-quality data to the market to 21Shares’ stakeholders is paramount to ensuring market participants can correctly price with confidence the liquidity profiles investors demand in actively growing crypto markets. 21Shares, the Swiss innovation-led crypto ETP issuer, whose product range includes Bitcoin, Ethereum, as well as HODL Basket ETP and its newly launched Stellar and Cardano Bitcoin ETPs, is opening up investment in cryptocurrencies which currently lists 14 ETPs on the Zurich SIX as well Frankfurt and Vienna exchanges. 21Shares’s goal is to expand its network...

Paris, May 31, 2021, 8:30 am PRESS RELEASE Eramet includes its Purpose in its statutes: Become a reference for the responsible transformation of the Earth’s mineral resources, for living well together Eramet’s Combined General Shareholders’ Meeting, which took place behind closed doors on May 28, 2021 in Paris under the chairmanship of Ms. Christel Bories, Chair and CEO of Eramet, approved the registration of the purpose in article 3 of the company’s statutes 1. As Christel Bories notes: “Our purpose sets a course. By including it in the company’s statutes, we are taking a decisive step in Eramet’s transformation project, a socially responsible, committed and contributory corporate citizen. Conveying both our DNA and our collective ambition, it fuels our vision and the daily actions of all employees and stakeholders...

Company announcement no. 17 / 2021Schindellegi, Switzerland – 31 May 2021 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering memorandum or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017. The offer to acquire securities pursuant to any offering is made, and any investor should make his investment decision, solely on the basis of information that is contained in a prospectus made generally available in Denmark in connection with the offering. Copies of the prospectus may be obtained by persons in Denmark through the website of the Company as set forth elsewhere in this announcement. Completion...

Kinnevik AB (publ) (“Kinnevik”) today announced that as of 31 May 2021 the total number of shares in the company amounts to 556,242,088, and the total number of votes in the company amounts to 1,163,839,864. The Annual General Meeting of Kinnevik on 29 April 2021 resolved to distribute Kinnevik’s shareholding in Zalando to its shareholders through a share redemption plan. The share redemption plan involves a share split (2:1) whereby each existing share in the company has been split into two new shares. The share split has resulted in that the number of shares in Kinnevik has increased by 278,121,044 shares during May 2021. The 278,121,044 new shares are redemption shares which will be redeemed as part of the share redemption plan. Thereafter the number of shares in Kinnevik will amount to 278,121,044, the same number...

The financial results of AUGA group, AB and its subsidiaries (hereinafter – the Group) improved, revenues and profitability increased. The aggregate sales of the Group amounted to EUR 19.48 million in the first quarter of 2021, representing a 14% increase on the same period last year, when aggregate sales were EUR 17.04 million. During the first three-months of 2021, the gross profit of the Group amounted to EUR 4.51 million. This marks a 21% rise on the equivalent period the previous year, when gross profit was EUR 3.74 million. In 2021, the Group earned a EUR 0.67 million net profit, compared with EUR 0.18 million a year earlier. In 2021, the Group’s EBITDA amounted to EUR 5.74 million, representing a 16% uplift compared with the previous year, when EBITDA was EUR 4.95 million.Main financial results, EUR million 3 months...

The compliance of banks with MREL requirements – Q1 2021 At the end of the first quarter, all banks complied with the minimum requirements for own funds and eligible liabilities (MREL requirements) set by the Swedish National Debt Office. This is presented in the Debt Office’s latest quarterly report published today. If a systemically important bank or financial institution experiences a crisis, the Debt Office can assume control of it and implement crisis management measures to safeguard financial stability. This procedure, called resolution, is intended to enable the central government to manage an institution in crisis without having to resort to using taxpayers’ money to rescue it. Instead, the institution’s shareholders and investors are to bear the costs of crisis management. Requirements for a certain amount of own funds and liabilities As...

This newly formed committee of international specialists will advise on the scientific and clinical aspects related to the development of Onxeo’s current and future programs PARIS, May 31, 2021 (GLOBE NEWSWIRE) — Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in the fields of DDR, resistance to treatment and more globally, drug development in oncology. The Committee will advise and guide the Company as it advances its proprietary platform of compounds in the DDR field and develops innovative therapeutics that address unmet medical needs and...